A Single Center, Phase I Study to Follow-up on the Change of Immunogenicity and Lesion Condition in Subjects Who Have Completed the Phase I GX-188E Trial (Protocol no. GX-188E-SN)

Trial Profile

A Single Center, Phase I Study to Follow-up on the Change of Immunogenicity and Lesion Condition in Subjects Who Have Completed the Phase I GX-188E Trial (Protocol no. GX-188E-SN)

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Jul 2017

At a glance

  • Drugs GX 188E (Primary)
  • Indications Cervical intraepithelial neoplasia
  • Focus Therapeutic Use
  • Acronyms GX-188E-FU
  • Sponsors Genexine
  • Most Recent Events

    • 11 Jul 2017 Planned End Date changed from 31 Dec 2017 to 1 Jan 2018.
    • 11 Jul 2017 Planned primary completion date changed from 31 Aug 2017 to 1 Jan 2018.
    • 21 Apr 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top